Cargando…

miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+ Breast Cancer

SIMPLE SUMMARY: Resistance to anti-HER2+ therapy remains the main clinical challenge in the management of the HER2+ breast cancer subtype. The objective of our study was to analyze the involvement of microRNAs in the resistance to trastuzumab. We identified miR-146a-5p as the major dysregulated micr...

Descripción completa

Detalles Bibliográficos
Autores principales: Cabello, Paula, Torres-Ruiz, Sandra, Adam-Artigues, Anna, Forés-Martos, Jaume, Martínez, María Teresa, Hernando, Cristina, Zazo, Sandra, Madoz-Gúrpide, Juan, Rovira, Ana, Burgués, Octavio, Rojo, Federico, Albanell, Joan, Lluch, Ana, Bermejo, Begoña, Cejalvo, Juan Miguel, Eroles, Pilar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093389/
https://www.ncbi.nlm.nih.gov/pubmed/37046799
http://dx.doi.org/10.3390/cancers15072138
_version_ 1785023574380118016
author Cabello, Paula
Torres-Ruiz, Sandra
Adam-Artigues, Anna
Forés-Martos, Jaume
Martínez, María Teresa
Hernando, Cristina
Zazo, Sandra
Madoz-Gúrpide, Juan
Rovira, Ana
Burgués, Octavio
Rojo, Federico
Albanell, Joan
Lluch, Ana
Bermejo, Begoña
Cejalvo, Juan Miguel
Eroles, Pilar
author_facet Cabello, Paula
Torres-Ruiz, Sandra
Adam-Artigues, Anna
Forés-Martos, Jaume
Martínez, María Teresa
Hernando, Cristina
Zazo, Sandra
Madoz-Gúrpide, Juan
Rovira, Ana
Burgués, Octavio
Rojo, Federico
Albanell, Joan
Lluch, Ana
Bermejo, Begoña
Cejalvo, Juan Miguel
Eroles, Pilar
author_sort Cabello, Paula
collection PubMed
description SIMPLE SUMMARY: Resistance to anti-HER2+ therapy remains the main clinical challenge in the management of the HER2+ breast cancer subtype. The objective of our study was to analyze the involvement of microRNAs in the resistance to trastuzumab. We identified miR-146a-5p as the major dysregulated microRNA among parental and trastuzumab-resistant HER2+ breast cancer cells. The gain- and loss-of-function of this miRNA modulates resistance to trastuzumab in vitro, and elevated levels of miR-146a-5p in the primary tumor have been associated with a poor prognosis. In addition, exosomes from trastuzumab-resistant cells contain high levels of miR-146a-5p, and may reduce the effect of trastuzumab on sensitive cancer cells, increasing the expression of epithelial-to-mesenchymal transition markers and the capacities for migration and angiogenesis. The results of this study demonstrate for the first time the involvement of miR-146a-5p in resistance to trastuzumab, and suggest that exosomes play an important role in this process. ABSTRACT: Trastuzumab treatment has significantly improved the prognosis of HER2-positive breast cancer patients. Despite this, resistance to therapy still remains the main clinical challenge. In order to evaluate the implication of microRNAs in the trastuzumab response, we performed a microRNA array in parental and acquired trastuzumab-resistant HER2-positive breast cancer cell lines. Our results identified miR-146a-5p as the main dysregulated microRNA. Interestingly, high miR-146a-5p expression in primary tumor tissue significantly correlated with shorter disease-free survival in HER2-positive breast cancer patients. The gain- and loss-of-function of miR-146a-5p modulated the response to trastuzumab. Furthermore, the overexpression of miR-146a-5p increased migration and angiogenesis, and promoted cell cycle progression by reducing CDKN1A expression. Exosomes from trastuzumab-resistant cells showed a high level of miR-146a-5p expression compared with the parental cells. In addition, the co-culture with resistant cells’ exosomes was able to decrease in sensitivity and increase the migration capacities in trastuzumab-sensitive cells, as well as angiogenesis in HUVEC-2 cells. Collectively, these data support the role of miR-146a-5p in resistance to trastuzumab, and demonstrate that it can be transferred by exosomes conferring resistance properties to other cells.
format Online
Article
Text
id pubmed-10093389
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100933892023-04-13 miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+ Breast Cancer Cabello, Paula Torres-Ruiz, Sandra Adam-Artigues, Anna Forés-Martos, Jaume Martínez, María Teresa Hernando, Cristina Zazo, Sandra Madoz-Gúrpide, Juan Rovira, Ana Burgués, Octavio Rojo, Federico Albanell, Joan Lluch, Ana Bermejo, Begoña Cejalvo, Juan Miguel Eroles, Pilar Cancers (Basel) Article SIMPLE SUMMARY: Resistance to anti-HER2+ therapy remains the main clinical challenge in the management of the HER2+ breast cancer subtype. The objective of our study was to analyze the involvement of microRNAs in the resistance to trastuzumab. We identified miR-146a-5p as the major dysregulated microRNA among parental and trastuzumab-resistant HER2+ breast cancer cells. The gain- and loss-of-function of this miRNA modulates resistance to trastuzumab in vitro, and elevated levels of miR-146a-5p in the primary tumor have been associated with a poor prognosis. In addition, exosomes from trastuzumab-resistant cells contain high levels of miR-146a-5p, and may reduce the effect of trastuzumab on sensitive cancer cells, increasing the expression of epithelial-to-mesenchymal transition markers and the capacities for migration and angiogenesis. The results of this study demonstrate for the first time the involvement of miR-146a-5p in resistance to trastuzumab, and suggest that exosomes play an important role in this process. ABSTRACT: Trastuzumab treatment has significantly improved the prognosis of HER2-positive breast cancer patients. Despite this, resistance to therapy still remains the main clinical challenge. In order to evaluate the implication of microRNAs in the trastuzumab response, we performed a microRNA array in parental and acquired trastuzumab-resistant HER2-positive breast cancer cell lines. Our results identified miR-146a-5p as the main dysregulated microRNA. Interestingly, high miR-146a-5p expression in primary tumor tissue significantly correlated with shorter disease-free survival in HER2-positive breast cancer patients. The gain- and loss-of-function of miR-146a-5p modulated the response to trastuzumab. Furthermore, the overexpression of miR-146a-5p increased migration and angiogenesis, and promoted cell cycle progression by reducing CDKN1A expression. Exosomes from trastuzumab-resistant cells showed a high level of miR-146a-5p expression compared with the parental cells. In addition, the co-culture with resistant cells’ exosomes was able to decrease in sensitivity and increase the migration capacities in trastuzumab-sensitive cells, as well as angiogenesis in HUVEC-2 cells. Collectively, these data support the role of miR-146a-5p in resistance to trastuzumab, and demonstrate that it can be transferred by exosomes conferring resistance properties to other cells. MDPI 2023-04-04 /pmc/articles/PMC10093389/ /pubmed/37046799 http://dx.doi.org/10.3390/cancers15072138 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Cabello, Paula
Torres-Ruiz, Sandra
Adam-Artigues, Anna
Forés-Martos, Jaume
Martínez, María Teresa
Hernando, Cristina
Zazo, Sandra
Madoz-Gúrpide, Juan
Rovira, Ana
Burgués, Octavio
Rojo, Federico
Albanell, Joan
Lluch, Ana
Bermejo, Begoña
Cejalvo, Juan Miguel
Eroles, Pilar
miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+ Breast Cancer
title miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+ Breast Cancer
title_full miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+ Breast Cancer
title_fullStr miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+ Breast Cancer
title_full_unstemmed miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+ Breast Cancer
title_short miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+ Breast Cancer
title_sort mir-146a-5p promotes angiogenesis and confers trastuzumab resistance in her2+ breast cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093389/
https://www.ncbi.nlm.nih.gov/pubmed/37046799
http://dx.doi.org/10.3390/cancers15072138
work_keys_str_mv AT cabellopaula mir146a5ppromotesangiogenesisandconferstrastuzumabresistanceinher2breastcancer
AT torresruizsandra mir146a5ppromotesangiogenesisandconferstrastuzumabresistanceinher2breastcancer
AT adamartiguesanna mir146a5ppromotesangiogenesisandconferstrastuzumabresistanceinher2breastcancer
AT foresmartosjaume mir146a5ppromotesangiogenesisandconferstrastuzumabresistanceinher2breastcancer
AT martinezmariateresa mir146a5ppromotesangiogenesisandconferstrastuzumabresistanceinher2breastcancer
AT hernandocristina mir146a5ppromotesangiogenesisandconferstrastuzumabresistanceinher2breastcancer
AT zazosandra mir146a5ppromotesangiogenesisandconferstrastuzumabresistanceinher2breastcancer
AT madozgurpidejuan mir146a5ppromotesangiogenesisandconferstrastuzumabresistanceinher2breastcancer
AT roviraana mir146a5ppromotesangiogenesisandconferstrastuzumabresistanceinher2breastcancer
AT burguesoctavio mir146a5ppromotesangiogenesisandconferstrastuzumabresistanceinher2breastcancer
AT rojofederico mir146a5ppromotesangiogenesisandconferstrastuzumabresistanceinher2breastcancer
AT albanelljoan mir146a5ppromotesangiogenesisandconferstrastuzumabresistanceinher2breastcancer
AT lluchana mir146a5ppromotesangiogenesisandconferstrastuzumabresistanceinher2breastcancer
AT bermejobegona mir146a5ppromotesangiogenesisandconferstrastuzumabresistanceinher2breastcancer
AT cejalvojuanmiguel mir146a5ppromotesangiogenesisandconferstrastuzumabresistanceinher2breastcancer
AT erolespilar mir146a5ppromotesangiogenesisandconferstrastuzumabresistanceinher2breastcancer